Lichen Planus
An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.
Subtype terms (1)
More specific conditions that are subtypes of Lichen Planus in the MeSH hierarchy.
- Lichen Planus, Oral
67 drugs (31 approved, 36 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (5)
Phase 2 trials (19)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (43)
- Actelion
- Celgene
- Biogen
- Novartis
- Virginia Clinical Research, Inc.
- National Institutes of Health (NIH)
- National Institute of Dental and Craniofacial Research (NIDCR)
- Case Western Reserve University
- Harvard University
- Eastern Virginia Medical School
- Emory University
- Mashhad University of Medical Sciences
- October 6 University
- Oregon Health and Science University
- Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
- Stanford University
- Tufts University
- University of Florida
- University of Louisville
- University of Michigan
- University of Oslo
- University of Peradeniya
- University of Rochester
- University of Toronto
- Wake Forest University
- University of Zagreb
- University of Zurich
- Mayo Clinic
- College of Dental Sciences, India
- Qazvin University Of Medical Sciences
- +13 more
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (10)